🟢 Definium Therapeutics is trading 4.03% up today after positive Phase 3 Voyage results

Definium Therapeutics is trading 4.03% up now at $44.52 after positive Phase 3 Voyage results announced August 12, 2026.

• The DT120 ODT study met its primary and all key secondary endpoints, delivering a 5.4-point placebo-adjusted HAM-A improvement (p<0.0001).
• The company reported generally favorable tolerability, while Reuters described the results as exceeding investor expectations.
• The move follows a 4.60% gain on August 12, 2026, despite only modestly positive broader-market conditions.